医药情绪回暖，创新药产业链仍是2026年主线：医药生物

Investment Rating - The industry rating is "Outperform the Market" [8] Core Insights - The sentiment in the pharmaceutical sector is recovering, with the innovative drug industry chain expected to be the main focus in 2026 [3] - The report highlights that the pharmaceutical index has underperformed compared to the CSI 300 index, with a decline of 2.5% in the week of March 2-6, 2026 [4] - The report suggests that the rising prices of synthetic vitamins, driven by international oil price increases, may have strong sustainability [5][25] - The report emphasizes the importance of innovative drugs and medical devices as key investment directions for 2026, with a focus on revenue realization, unexpected data, and advanced technology platforms [6] Summary by Sections Market Review - The CITIC Pharmaceutical Index fell by 2.5% in the week of March 2-6, 2026, underperforming the CSI 300 index by 1.5 percentage points [4] - The top-performing stocks during this period included Yahui Pharmaceutical (+38.1%), New Harmony (+15.2%), and Zhejiang Pharmaceutical (+12.8%) [52] Vitamin Price Trends - The production of vitamins is primarily divided into biological fermentation and chemical synthesis, with the latter heavily reliant on petrochemical raw materials [5][19] - Prices for synthetic vitamins are expected to rise due to increased oil prices, with notable price increases for niacinamide (up 18.5% to 48 CNY/kg) and vitamin E (up 12.3% to 64 CNY/kg) [22] - The report recommends focusing on companies such as Yifang Pharmaceutical, New Harmony, and Zhejiang Pharmaceutical due to their positions in the vitamin market [5][32] Investment Strategy - The report outlines a strategy for 2026 focusing on innovative drugs and medical devices, with specific attention to companies that can benefit from price increases or exceed performance expectations [6] - Suggested stocks for investment include Kangfang Biotech, Yao Ming Kangde, and Jichuan Pharmaceutical, among others [6][14]